NEW YORK (GenomeWeb News) – Personalized medicine startup Medomics said this week that it is in discussions with various undisclosed entities to raise $3 million to $4 million to further develop and market its gene sequencing-based diagnostic test for mitochondrial diseases.

Medomics, based in Azusa, Calif., expects to receive a $1 million investment from an undisclosed corporate co-investor if it can raise $2 million to $3 million in financing from additional investors, Steve Sommer, president and founder of Medomics, told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.